Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nafamostat in hospitalized COVID-19 patients
NCT04352400Phase 3Unknown
- Sponsor
- Azienda Ospedaliero-Universitaria di Padova
- Start
- Jun 2021
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Nafamostat with Placebo (2 arms). Primary endpoint: Time-to-clinical improvement. Status: unknown.
02
Drugs
Nafabelltan
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04352400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04352400.